In lung adenocarcinoma patients with EGFR mutations, Ma et al. reported that elevated pre-treatment bilirubin was associated with longer PFS (HR, 0.454; 95% CI 0.267–0.773; p = 0.004) [28], whereas Zhang et al. reported that pre-treatment DB was a significant risk factor in advanced NSCLC patients with EGFR mutations (HR, 1.68; 95% CI: 1.22–2.30; p = 0.001) [29]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.